You just read:

Janssen Announces U.S. FDA Approval Of TREMFYA™ (Guselkumab) For The Treatment Of Moderate To Severe Plaque Psoriasis

News provided by

Janssen Biotech, Inc.

Jul 13, 2017, 16:10 ET